Kite Pharma (NASDAQ: KITE) is gaining 6.1% off the open amid manufacturing shortcomings from competitor Novartis' (NYSE: NVS) CTL019's JULIET.Cowen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE